TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03467919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micro Fragmented Adipose Tissue
Description: Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
Study: NCT02162277

Intervention type: DEVICE
Intervention: diagnostic osteoporotic kit ( including 7 genes and 4 life styles)
Description: Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
Study: NCT01294774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP203 - 1.2mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KRP203 - 1.2 mg
Study: NCT03342378

Intervention type: RADIATION
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI
Description: All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
Study: NCT01946828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIM
Description: Field Induced Mydriasis device
Study: NCT01664637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg TZP-102
Description: One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
Study: NCT00218387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 200mg Modafinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400mg Modafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study: NCT05434988

Intervention type: PROCEDURE
Intervention: appendectomy
Description: Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)

Intervention type: PROCEDURE
Intervention: appendectomy
Description: Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
Study: NCT04882813

Intervention type: DRUG
Intervention: Dapagliflozin
Description: Dapagliflozin dispensing claim is used as the exposure group.

Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin dispensing claim is used as the reference group.
Study: NCT02691923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein + ALA
Study: NCT02659423

Intervention type: BEHAVIORAL
Intervention: BIC 1
Description: BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.

Intervention type: BEHAVIORAL
Intervention: BIC 2
Description: BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.

Intervention type: BEHAVIORAL
Intervention: BIC 3
Description: BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
Study: NCT04138901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided subcostal transversus abdominis plane block (TAPB)
Description: At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Description: 0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Study: NCT02303795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
Study: NCT03555526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole, 500mg, tid, for 10 days (day 1-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline
Description: tetracycline 500mg, qid, for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline
Description: tetracycline 500mg, qid, for 10 days
Study: NCT01502722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion sugary and sweetened drinks on thirst
Description: The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion sugary and sweetened drinks on thirst
Description: The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion sugary and sweetened drinks on thirst
Description: The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
Study: NCT03756766

Intervention type: DIAGNOSTIC_TEST
Intervention: RSV point of care testing
Description: Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
Study: NCT01208233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03049423
Description: 1 mg of PF-03049423 daily for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03049423
Description: 3 mg of PF-03049423 daily for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03049423
Description: 6 mg of PF-03049423 daily for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of PF-03049423 daily for 90 days
Study: NCT00674141

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone soduim phosphate
Description: nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
Study: NCT03184792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous spinal stimulation
Description: Non-invasive electrical stimulation of cervical spinal cord over the skin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy to improve arm and hand functions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy to improve arm and hand functions
Study: NCT03281811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid Hydrochloride
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT00797615

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active intervention
Description: 12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alternative Intervention
Description: 12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
Study: NCT03735394

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonic probe
Description: apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
Study: NCT01795508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMTO
Description: Parent Management Training, Oregon

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Other kinds of family training
Study: NCT03904979

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing exercises
Description: Participants will be given journals with writing prompts to be completed throughout their pregnancy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Writing exercises
Description: Participants will be given journals with writing prompts to be completed throughout their pregnancy.
Study: NCT02287415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study: NCT00315094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiving support interventions (FamTechCare)
Description: One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
Study: NCT04368598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine, po, 400mg tid, for 4 weeks
Study: NCT01769157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00459134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ArginMax
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT03145272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
Study: NCT01713777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Generic A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Generic A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine generic B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine generic B
Study: NCT03181516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12
Description: Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Yogurt without Bifidobacterium animalis subsp. lactis BB-12
Study: NCT03734198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
Study: NCT01947504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and support intervention
Study: NCT01242904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimodal solution
Description: 200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icodextrin
Description: 200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Study: NCT04176796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival
Description: The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
Study: NCT01584050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-5-methyltetrahydrofolate (Metafolin ®)
Description: dosage: 1000 μg, frequency: once daily, duration: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: dosage: 1000 μg, frequency: once daily, duration: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: frequency: once daily, duration: 12 weeks
Study: NCT00216073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 po bid, days 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
Study: NCT02932397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dose of 0.5 mg/kg of propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous dose of 0.05 mL/kg of saline solution
Study: NCT04465175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Second dose magnesium sulphate infusion over one hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (2.5 ml/kg) infusion over one hour
Study: NCT00518011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: As prescribed
Study: NCT04560504

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Leisure activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oculomotor Training Group
Description: Eye movement training
Study: NCT03065465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope hemoclipping device
Description: A endoscopic entrapment of tissue for control of bleeding or other applications.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard endoscopic treatment
Description: Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
Study: NCT01331148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo with daily calcium/Vitamin D soft chews
Study: NCT03175224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.
Study: NCT02415634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECAP
Description: Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
Study: NCT03175224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.
Study: NCT02189200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oat bran - 40g
Description: oat bran - 40g per day
Study: NCT03175224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.
Study: NCT04414384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: Abdominal Binder placement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step Counter
Description: step counter to track steps
Study: NCT02189200

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: refined rice flour- 40g
Description: refined rice flour - 40g per day